The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - Trends in HCV testing and the impact of HCV on HIV treatment outcomes

Journal of Viral Hepatitis

Volumn 17, Issue 8, 2010, Pages 569-577

  Turner, J ^a   Bansi, L ^b   Gilson, R ^a   Gazzard, B ^c   Walsh, J ^d   Pillay, D ^e   Orkin, C ^f   Phillips, A ^b   Easterbrook, P ^g   Johnson, M ^h   Porter, K ⁱ   Schwenk, A ^j   Hill, T ^b   Leen, C ^k   Anderson, J ^l   Fisher, M ^m   Sabin, C ^b  

^a Camden Primary Care Trust   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f BARTS HEALTH NHS TRUST   (United Kingdom)

^g KING S COLLEGE HOSPITAL   (United Kingdom)

^h ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

ⁱ MEDICAL RESEARCH COUNCIL   (United Kingdom)

^j NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^k NHS LOTHIAN   (United Kingdom)

^l HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^m UK   (United Kingdom)

more..

Author keywords

cohort; HCV; hepatitis C; HIV

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS ANTIBODY; HEPATITIS C ANTIBODY;

ADULT; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED KINGDOM; BLOOD; COHORT ANALYSIS; COMPLICATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; ISOLATION AND PURIFICATION; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL; TRENDS; VIROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; GREAT BRITAIN; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; PROPORTIONAL HAZARDS MODELS; SEROEPIDEMIOLOGIC STUDIES;

EID: 77954491942     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01215.x     Document Type: Article

References (28)

1. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001 32 : 492 497.
2. Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000 356 : 1800 1805.
3. Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997 26 : 1 5.
4. Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999 30 : 1054 1058. (Pubitemid 29458296)
5. deSilva S, Brook MG, Curtis H, Johnson M. Survey of HIV and hepatitis B or C co-infection management in the UK 2004. Int J STD AIDS 2006 17 : 799 801.
6. Mohsen AH, Murad S, Easterbrook PJ. Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London. HIV Med 2005 6 : 206 215.
7. Martin-Carbonero L, Benhamou Y, Puoti M et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004 38 : 128 133.
8. Piroth L, Duong M, Quantin C et al. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 1998 12 : 381 388.
9. Macias J, Pineda JA, Lozano F et al. Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naive patients coinfected with human immunodeficiency virus and hepatitis C virus. Eur J Clin Microbiol Infect Dis 2003 22 : 675 680.
10. Rockstroh JK, Mocroft A, Soriano V et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005 192 : 992 1002.
11. Martinez E, Blanco JL, Arnaiz JA et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001 15 : 1261 1268.
12. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Elevated liver enzymes following initiation of antiretroviral therapy. JAMA 2000 283 : 2526 2527.
13. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000 283 : 74 80.
14. Brau N, Salvatore M, Rios-Bedoya CF et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006 44 : 47 55.
15. Qurishi N, Kreuzberg C, Luchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003 362 : 1708 1713.
16. Brook MG. Summary of BHIVA guidelines for HIV and hepatitis B or C co-infection. J HIV Ther 2003 8 : 85 88.
17. Nelson M, Matthews G, Brook MG, Main J. BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection (2005). HIV Med 2005 6 : 96 106. (Pubitemid 41038588)
18. UK Collaborative HIV Cohort Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004 5 : 115 124.
19. Saves M, Vandentorren S, Daucourt V et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe d'Epidemiologie Clinique de Sida en Aquitaine (GECSA). AIDS 1999 13 : F115 F121.
20. Gilson R, Man S-L, Copas A et al. Discordant response on starting HAART: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort Study (UK CHIC). HIV Med in press. Epub 2009 Sep 1.
21. Perez Cachafeiro S, Del Amo J, Iribarren J et al. Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006. Clin Infect Dis 2009 48 : 1467 1470.
22. Brook G, Main J, Nelson M et al. British HIV Association Guidelines for the Management of Co-infection with HIV-1 and Chronic Hepatitis B or C 2009. British HIV Association cited 2009, Jun 16]; Available at: http://www.bhiva.org/ files/file1031815.pdf
23. Health Protection Agency Centre for Infections. Hepatitis C in the UK 2008.
24. Miller MF, Haley C, Koziel MJ, Rowley CF. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis 2005 41 : 713 720.
25. Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1997 1 : 559 568.
26. Soriano V, Puoti M, Sulkowski M et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007 21 : 1073 1089.
27. Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000 284 : 450 456.
28. Zinkernagel AS, von Wyl V, Ledergerber B et al. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antivir Ther 2006 11 : 131 142.